Impact of vertical banded gastroplasty on body weight, insulin resistance, adipocytokine, inflammation and metabolic syndrome markers in morbidly obese patients

Endokrynologia Polska

Volumn 62, Issue 2, 2011, Pages 109-119

  Jankiewicz Wika, Joanna ^a   Kołomecki, Krzysztof ^a   Cywiński, Jacek ^b   Piestrzeniewicz, Katarzyna ^a   Świȩtosławski, Jacek ^a   Stȩpień, Henryk ^a   Komorowski, Jan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Nicolaus Copernicus Hospital   (Poland)

Author keywords

Adiponectin; Bariatric surgery; Ghrelin; Leptin; Metabolic syndrome; Morbid obesity; Resistin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GHRELIN; GLUCOSE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; DIASTOLIC BLOOD PRESSURE; FEMALE; GASTROPLASTY; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MORBID OBESITY; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VERTICAL BANDED GASTROPLASTY; WAIST CIRCUMFERENCE;

ADIPOKINES; ADULT; BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; FEMALE; GASTROPLASTY; GHRELIN; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, MORBID; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 79956357889     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Flegal KM, Carroll MD, Ogden CL et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
2. Gaziano JM. Fifth phase of the epidemiologic transition. The age of obesity and inactivity. JAMA 2010; 303: 275-276.
3. Wang Y, Beydoun MA, Liang L et al. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity 2008; 16: 2323-2330.
4. Lewis KK, Man LH. Overweight and obesity in Massachusetts: epidemic, hype or policy opportunity? Issue Brief (Mass Health Policy Forum). 2007; 30: 1-29.
5. Main ML, Rao S C, O'Keefe J H. Trends in obesity and extreme obesity among US adults. JAMA 2010; 303: 1695-1696.
6. Carr CC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk J Clin Endocrinol Metab 2004; 89: 2601-2607.
7. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595-2600. (Pubitemid 38766337)
8. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome 2005. www.idf.org
9. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003; 24: 276-283.
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998; 15: 539-553.
11. National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
12. Barzilai N, She L, Liu B Q et al. Surgical removal of visceral fat reverses hepatic insulin resistance Diabetes1999; 48: 94-98.
13. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006; 580: 2917-2921. (Pubitemid 43729162)
14. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004; 68: 975-981.
15. Jankiewicz-Wika J, Kołomecki K, Cywinski J et al. The relationship between features of metabolic syndrome and blood adipocytokine concentrations in morbidly obese patients during dynamic weight loss. Central Eur J Med. 2006; 1: 136-147. (Pubitemid 44198237)
16. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA 2002; 288: 2793-2796. (Pubitemid 35425059)
17. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120: 669v681.
18. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2002; 89: 2608-2615.
19. Shah M, Simha V, Garg A. Review: Long-term impact of bariatric surgery on body weight, comorbibities, and nutritional status. J Clin Endorinol Metab 2006; 91: 4223-4231. (Pubitemid 44833388)
20. Trakhenbroit MA, Leichman JG, Algahim MF et al. Body weight, insulin resistance, and serum adipokine levels two years after two types of bariatric surgery. Am J Med 2009; 122: 435-442.
21. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. Obes Res 1998; 6 (Suppl. 2): 51S-209S.
22. North American Association for the Study of Obesity and the National Heart, Lung, and Blood Institute. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. NIH publication 2000; 00-4084
23. Santry H P, Gillen D L, Lauderdale D S. Trends in bariatric surgical procedures. JAMA 2005; 294: 1909-1917. (Pubitemid 41464692)
24. Steinbrook R Surgery for severe obesity. N Engl J Med 2004; 350: 1075-1079.
25. Picot J, Jones J, Colquitt JL et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 215-357.
26. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737 (Pubitemid 39346675)
27. Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693. (Pubitemid 39665322)
28. Sjöström L, Narbro K, Sjöström D et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
29. Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Annals of Internal Medicine 2005; 142: 547-559.
30. Sugerman HJ, Starkey J V. Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Annals of Surgery 1987; 205: 613-624. (Pubitemid 17103382)
31. Hall JC, Watts JM, O'Brien PE et al. Gastric surgery for morbid obesity. The Adelaide study. Ann Surg 1990; 211: 419-427.
32. Pories WJ, Flickinger EG, Meelheim D et al. The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion. Ann Surg 1982; 196: 389-399. (Pubitemid 12030716)
33. Naslund I, Wickbom G, Christoffersson E et al. A prospective randomized comparison of gastric bypass and gastroplasty. Complications and early results. Acta Chir Scand 1986; 152: 681-689.
34. Howard L, Malone M, Michalek A et al. Gastric bypass and vertical banded gastroplasty - a prospective randomized comparison and 5-year follow-up. Obesity Surg 1995; 5: 55-60.
35. Morino M, Toppino M, Bonnet G et al. Laparoscopic adjustable silicone gastric banding versus vertical banded gastroplasty in morbidly obese patients: a prospective randomized controlled clinical trial. Ann Surg 2003; 238: 835-841.
36. Ballantyne GH, Farkas D, Laker S et al. Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass. Obesity Surg 2006; 16: 1189-1197. (Pubitemid 44433156)
37. Dixon J B, Dixon A F, O'Brien P E. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diabet Med 2003; 20: 127-134. (Pubitemid 36269654)
38. Guidone C, Manco M, Valera-Mora E et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025-2031. (Pubitemid 44509976)
39. Polyzogopoulou EV, Kalfarentzos F, Vagenakis A et al. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003; 52: 1098-1103. (Pubitemid 36523342)
40. Fujimoto S, Abbate S, Kahn J et al. The visceral adiposity syndrome in Japanese-American men. Obes Res 1994; 2: 364-371.
41. Ruderman, D. Chisholm, X. Pi-Sunyer et al. The metabolically obese, normal-weight individuals revisited. Diabetes 1998; 47: 699-713. (Pubitemid 28201798)
42. Kelesidis T, Kelesidis I, Chou S et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152: 93-100.
43. Harvey J, Ashford MLJ. Leptin in CNS: much more than a satiety signal. Neuropharmacology 2003; 44: 845-854. (Pubitemid 36515020)
44. Komorowski J, Jankiewicz-Wika J, Stȩpień H. Effects of Gn-RH, TRH, and CRF administration on plasma leptin levels in lean and obese women. Neuropeptides 2006; 34: 89-97.
45. Ten S, MacLaren N. Insulin resistance in children. J Clin Endocrinol Metab 2004; 89: 2526-2539.
46. Molina A, Vendrell J, Gutierrez C et al. Insulin resistance, leptin and TNF-α system in morbidly obese women after gastric bypass. Obes Surg 2003; 13: 615-621. (Pubitemid 36951744)
47. Infanger D, Baldinger R, Branson R et al. Effect of significant intermediate-term weight loss on serum leptin levels and body composition in severely obese subjects. Obes Surg 2003; 13: 879-888. (Pubitemid 38010709)
48. Nijhuis J, van Dielen FM, Buurman W A et al. Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes Surg 2004; 14: 783-787. (Pubitemid 38982263)
49. Uzun H, Zengin K, Taskin M et al. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004; 14: 659-665. (Pubitemid 38716588)
50. Coupaye M, Bouillot JL, Coussieu C et al. One-year changes in energy expenditure and serum leptin following adjustable gastric banding in obese women. Obes Surg 2005; 15: 827-833. (Pubitemid 40904874)
51. Korner J, Bessler M, Cirilo LJ et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90: 359-365. (Pubitemid 40116682)
52. Shetty GK, Economides PA, Horton ES et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457. (Pubitemid 39281400)
53. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83. (Pubitemid 29299050)
54. Yamamoto Y, Hirose Y, Saito I et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103: 132-147.
55. Matsubara M, Maruka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147: 173-180.
56. Polak J, Kovacova Z, Holst C et al. Total adiponectin and adiponectin multimeric complexes in relation to weight loss-induced improvements in insulin sensitivity in obese women: the NUGENOB study. Eur J Endocrinol 2008; 158: 533-541. (Pubitemid 351606349)
57. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312. (Pubitemid 32151228)
58. Steppan CM, Lazar M A, Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13: 18-23. (Pubitemid 36734011)
59. Ohmori R, Momiyama Y, Kato R et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005; 45: 379-380. (Pubitemid 40966873)
60. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866. (Pubitemid 34967064)
61. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946. (Pubitemid 32756432)
62. Blucher M, Michael MD, Peroni OD et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002; 3: 25-38. (Pubitemid 34778393)
63. Stefan N, Vozarova B, Funahashi T et al. Plasma adiponectin concentrations in association with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-1888. (Pubitemid 34564302)
64. Lindsay RS, Funahashi T, Hanson L R et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58. (Pubitemid 34756495)
65. Yokota T, Oritani K, Takahashi I et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-1732. (Pubitemid 30661055)
66. Ouchi N, Kichara S, Arilsa Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476. (Pubitemid 30005109)
67. Ouchi N, Kihara S, Ariata Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063. (Pubitemid 32200177)
68. Matsubara M, Maruka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal weight and obese women. Eur J Endocrinol 2002; 147: 173-180.
69. Owecki M, Miczke A, Nikisch E et al. Serum resistin concentrations are higher in human obesity but independent from insulin resistance. Exp Clin Endocrinol Diabetes 2010; 8. [Epub ahead of print].
70. Yuan T, Zhao Wei-gang, Sun Qi et al. Association between four adipokines and insulin sensitivity in patients with obesity, type 1 or type 2 diabetes mellitus, and in the general Chinese population. Chinese Med J 2010; 123: 2018-2022.
71. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metabol 2001; 86: 1930-1935. (Pubitemid 32472900)
72. Yu J G, Javorschi S, Havener A L et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetes subjects. Diabetes 2002; 51: 2968-2974.
73. Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499. (Pubitemid 37055444)
74. Janowska J, Zahorska-Markiewicz B, Olszanecka-Glinianowicz M. Relationship between serum resistin concentration and proinflammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism; 55: 1495-1499.
75. Harsch IA, Koebnick C, Wallaschofski H et al. Resistin levels in patients with obstructive sleep apnea syndrome - the link to subclinical inflammation? Med Sci Monit 2004; 10: CR510-515.
76. Zdrojewski T, Chwojnicki K, Bandosz P et al. Distribution of C-reactive protein and its relation to arterial hypertension in a country representing a high-risk region for cardiovascular disease. Blood Press 2006; 15: 20-26.
77. Toprak D, Toprak A, Chen W et al., Adiposity in childhood is related to c-reactive protein and adiponectin in young adulthood: from the Bogalusa Heart Study. Obesity 2010; doi: 10.1038/oby.2010.75 (published online 1 April 2010).
78. Boguszewski CL, Paz-Filho G, Velloso LA. Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and brain. Endokrynol Pol 2010; 61: 194-206.
79. Tschop M, Smiley DL, Heiman M L. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
80. Date Y, Kojima M, Hosoda H et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-4261.
81. Ariyasu H, Takaya K, Tagami T et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-4758. (Pubitemid 33020516)
82. Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
83. Barber TM, Casanueva FF, Karpe F et al. Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur J Endocrinol 2008; 158: 511-516. (Pubitemid 351606346)
84. Hanusch-Enserer U, Cauza E, Brabant G et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab 2004; 89: 3352-3358. (Pubitemid 38951903)
85. Mariani LM, Fusco A, Turriziani M et al. Transient increase of plasma ghrelin after laparoscopic adjustable gastric banding in morbid obesity. Horm Metab Res 2005; 37: 242-245. (Pubitemid 40756346)
86. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630. (Pubitemid 34755670)
87. Fruhbeck G, Diez-Caballero A, Gil MJ et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004; 14: 606-612. (Pubitemid 38716579)
88. Fruhbeck G, Rotellar F, Hernandez-Lizoain J L et al. Fasting plasma ghrelin concentrations six months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg 2004; 14: 1208-1215. (Pubitemid 39458595)
89. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89: 2608-2615. (Pubitemid 38766339)
90. Borg CM, le Roux CW, Ghatei MA et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93: 210-215. (Pubitemid 43259607)
91. Holdstock C, Engstrom BE, Ohrvall M et al. Effect of bariatric surgery on adipose tissue regulatory peptides and growth hormone secretion. Asia Pac J Clin Nutr 2004; 13: S41.